KR102733152B1 - 인플루엔자 ha 스플릿 백신의 제조 방법 - Google Patents

인플루엔자 ha 스플릿 백신의 제조 방법 Download PDF

Info

Publication number
KR102733152B1
KR102733152B1 KR1020207009033A KR20207009033A KR102733152B1 KR 102733152 B1 KR102733152 B1 KR 102733152B1 KR 1020207009033 A KR1020207009033 A KR 1020207009033A KR 20207009033 A KR20207009033 A KR 20207009033A KR 102733152 B1 KR102733152 B1 KR 102733152B1
Authority
KR
South Korea
Prior art keywords
influenza
split vaccine
vaccine
split
acid treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207009033A
Other languages
English (en)
Korean (ko)
Other versions
KR20200047629A (ko
Inventor
요시마사 다카하시
유 아다치
마나부 아토
Original Assignee
국립감염증연구소장이 대표하는 일본국
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 국립감염증연구소장이 대표하는 일본국 filed Critical 국립감염증연구소장이 대표하는 일본국
Priority claimed from PCT/JP2018/032537 external-priority patent/WO2019045090A1/ja
Publication of KR20200047629A publication Critical patent/KR20200047629A/ko
Application granted granted Critical
Publication of KR102733152B1 publication Critical patent/KR102733152B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207009033A 2017-09-04 2018-09-03 인플루엔자 ha 스플릿 백신의 제조 방법 Active KR102733152B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2017-169230 2017-09-04
JP2017169230 2017-09-04
JPJP-P-2018-137952 2018-07-23
JP2018137952A JP7403733B2 (ja) 2017-09-04 2018-07-23 インフルエンザｈａスプリットワクチンの製造方法
PCT/JP2018/032537 WO2019045090A1 (ja) 2017-09-04 2018-09-03 インフルエンザｈａスプリットワクチンの製造方法

Publications (2)

Publication Number Publication Date
KR20200047629A KR20200047629A (ko) 2020-05-07
KR102733152B1 true KR102733152B1 (ko) 2024-11-21

Family

ID=65815411

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207009033A Active KR102733152B1 (ko) 2017-09-04 2018-09-03 인플루엔자 ha 스플릿 백신의 제조 방법

Country Status (10)

Country Link
US (1) US11732031B2 (https=)
EP (1) EP3679948A4 (https=)
JP (1) JP7403733B2 (https=)
KR (1) KR102733152B1 (https=)
CN (1) CN111372605B (https=)
AU (1) AU2018325899B2 (https=)
CA (1) CA3074581A1 (https=)
EA (1) EA202090587A1 (https=)
PH (1) PH12020500414A1 (https=)
SG (1) SG11202001937TA (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
EA202192398A1 (ru) 2019-03-04 2021-11-23 Джэпэн Эз Репризентид Баи Директор Дженерал Оф Нэшнл Инститьют Оф Инфекшес Дизизис Способ приготовления сплит-вакцины против гриппа на основе гемагглютинина
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
CN121816361A (zh) 2023-04-26 2026-04-07 国立健康危机管理研究机构 抗流感抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098966A1 (en) * 2012-05-16 2015-04-09 Kj Biosciences Llc Influenza vaccines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010047509A2 (ko) 2008-10-24 2010-04-29 아주대학교 산학협력단 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물
CN101524538A (zh) * 2009-03-26 2009-09-09 成都康华生物制品有限公司 一种流感-大流行流感二价联合疫苗及其制备方法
EP3098236A1 (en) 2010-03-08 2016-11-30 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
BR112013025254A2 (pt) 2011-04-21 2016-09-06 Baxter Internat Inc E Baxter Healthcare S A método para isolar um antígeno de uma composição de vacina
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
AU2015305690A1 (en) 2014-08-18 2017-03-02 Sanofi Pasteur Inc. Alkylated influenza vaccines
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
JP7403733B2 (ja) 2017-09-04 2023-12-25 国立感染症研究所長 インフルエンザｈａスプリットワクチンの製造方法
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098966A1 (en) * 2012-05-16 2015-04-09 Kj Biosciences Llc Influenza vaccines

Also Published As

Publication number Publication date
EA202090587A1 (ru) 2020-08-24
AU2018325899B2 (en) 2023-04-20
EP3679948A1 (en) 2020-07-15
CN111372605A (zh) 2020-07-03
EP3679948A4 (en) 2021-04-28
AU2018325899A1 (en) 2020-04-09
CA3074581A1 (en) 2019-03-07
CN111372605B (zh) 2024-12-17
JP2019043937A (ja) 2019-03-22
JP7403733B2 (ja) 2023-12-25
KR20200047629A (ko) 2020-05-07
US20190345231A1 (en) 2019-11-14
PH12020500414A1 (en) 2021-03-08
SG11202001937TA (en) 2020-04-29
US11732031B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
KR102733152B1 (ko) 인플루엔자 ha 스플릿 백신의 제조 방법
KR101736897B1 (ko) 인플루엔자 항원 수송 벡터 및 구조물
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
US20230406910A1 (en) Method for producing influenza ha split vaccine
JP7545955B2 (ja) インフルエンザｈａスプリットワクチンの製造方法
CN111556896A (zh) 交叉免疫抗原疫苗及其制备方法
JP5730204B2 (ja) インフルエンザｍ２由来の改変ペプチドワクチン
JP7203015B2 (ja) 免疫原性組成物
KR101637955B1 (ko) 범용성 인플루엔자 바이러스 백신 조성물
TWI857017B (zh) 流感ha裂解疫苗之製造方法
Mardanova et al. High immunogenicity of plant-produced influenza based on the M2e peptide fused to flagellin
HK40032891A (en) Method for producing influenza ha split vaccine
KR101768600B1 (ko) 범용성 개 인플루엔자 바이러스 백신 조성물
EA045852B1 (ru) Способ получения сплит-вакцины с ha гриппа
CN111163801A (zh) 用于流感病毒的基于乙型肝炎纳米颗粒的疫苗
EA045912B1 (ru) Способ приготовления сплит-вакцины на основе гемагглютинина гриппа
HK40068192A (en) Method for preparing influenza ha split vaccine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20201224

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210901

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231215

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240827

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241119

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241119

End annual number: 3

Start annual number: 1

PG1601 Publication of registration